Published: May 30, 2026 · Last updated: May 30, 2026
- GLP-1 medications like semaglutide reduce hunger and slow gastric emptying, with weight loss as the most visible effect and metabolic improvements as the deeper one (Mayo Clinic, 2024)
- Improved insulin sensitivity from weight loss often restores menstrual cycles and fertility in women with PCOS and insulin-driven hormonal disruption (Johns Hopkins Medicine, 2024)
- GLP-1 drugs must be stopped at least two months before a planned pregnancy due to limited safety data in pregnant women (NIDDK, 2024)
The Ozempic conversation has been dominated by the headline (weight loss) and the loudest critiques (gastric paralysis, muscle loss, lifelong dependency). What gets buried is the more interesting story for women: GLP-1 drugs have meaningful effects on the hormonal system that go well beyond the scale.
Some of those effects are clearly beneficial. Some require active management. None of them get discussed honestly in most coverage, which leaves women making the decision with less information than they deserve.
What GLP-1 Drugs Actually Do
More Than an Appetite Suppressant: Semaglutide (Ozempic, Wegovy) and similar GLP-1 receptor agonists were developed for type 2 diabetes management. They stimulate insulin release, suppress glucagon, slow gastric emptying, and reduce appetite. NIDDK confirms that improved blood sugar control is the primary FDA-approved benefit (NIDDK, 2024).
Mayo Clinic notes that semaglutide produces weight loss as a side effect of these mechanisms, with about 20 percent of patients discontinuing the medication due to nausea, vomiting, diarrhea, or constipation. Most side effects decrease over time as the dose is gradually titrated (Mayo Clinic, 2024).
The hormonal effects of the drug extend beyond the GI tract. By improving insulin sensitivity and reducing chronic insulin elevation, it indirectly influences the reproductive and metabolic hormone landscape.
The PCOS and Fertility Story
Improved Insulin Sensitivity Often Restores Cycles: Polycystic ovary syndrome (PCOS) is driven in significant part by insulin resistance. Elevated insulin disrupts ovulation, increases androgen production, and produces the characteristic symptoms (irregular cycles, acne, excess hair growth, fertility difficulty).
Johns Hopkins Medicine's guidance on PCOS emphasizes that weight loss and improved insulin sensitivity often restore cycles and ovulation in patients whose PCOS is driven by insulin resistance (Johns Hopkins Medicine, 2024).
GLP-1 drugs improve both. For some women with PCOS, this means cycles resume, ovulation returns, and fertility improves (sometimes unexpectedly, which is the source of the "Ozempic babies" stories).
The Thyroid Considerations
Real Risk for a Small Subset of Women: Semaglutide carries an FDA warning about thyroid C-cell tumors based on rodent studies. The drug is contraindicated for women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
For the vast majority of women without these risk factors, the thyroid concern is theoretical rather than clinically demonstrated. Discuss thyroid history with your prescriber before starting.
The medication does not produce hypothyroidism or affect normal thyroid function in most patients. The warning is specifically about a rare tumor risk in patients with predisposing conditions.
The Pregnancy Question
Stop the Drug Two Months Before Conception: Semaglutide has limited safety data in pregnancy, and animal studies have raised concerns about fetal development. The standard medical guidance is to discontinue at least two months before a planned pregnancy due to the drug's long half-life.
This matters more than it sounds. The fertility-improving effect of weight loss and insulin sensitivity restoration can produce unintended pregnancies in women who assumed they were infertile.
If you are taking a GLP-1 drug and could become pregnant, use reliable contraception. If you are planning a pregnancy, talk to your doctor about timing the discontinuation safely.
The Honest Tradeoff for Women
Useful for the Right Patient, Not a Universal Solution: GLP-1 drugs work for the metabolic and hormonal patterns they were designed to address: insulin resistance, type 2 diabetes, significant obesity with metabolic complications. For women who fit this profile, the benefits often outweigh the side effects.
For women who do not fit this profile (those seeking modest cosmetic weight loss without metabolic dysfunction), the calculation is different. The side effects, the loss of skeletal muscle alongside fat, the long-term dependency question, and the cost all weigh against casual use.
The reasonable position: this is a real medication with real benefits and real tradeoffs. It should be prescribed by a clinician who knows your full medical picture, not treated as a lifestyle intervention.
To your health,
Ageless Coach
Age Strong. Live Long.
Trusted Sources Behind This Article
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.
Frequently Asked Questions
Want one verified-science article like this every week?
Get Better Health, Weekly